



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

The Binding Site  
c/o Mr. Jay H. Geller  
West Tower, Suite 4000  
2425 West Olympic Blvd  
Santa Monica, CA 90404

JUL 16 2004

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Re: k040466  
Trade/Device Name: Bindazyme® Human IgG Anti-Tissue Transglutaminase Enzyme  
Immunoassay Kit  
Bindazyme® Human IgA Anti-Tissue Transglutaminase Enzyme  
Immunoassay Kit  
Regulation Number: 21 CFR 866.5660  
Regulation Name: Multiple autoantibodies immunological test system  
Regulatory Class: Class II  
Product Code: MVM  
Dated: June 15, 2004  
Received: June 17, 2004

Dear Mr. Geller:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in cursive script that reads "Robert L. Becker, Jr.".

Robert L. Becker, Jr., M.D., Ph.D.

Director

Division of Immunology and Hematology Devices

Office of In Vitro Diagnostic Device Evaluation and Safety

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

Att. 7.1

Device Name: Bindazyme® Human IgG Anti-Tissue Transglutaminase  
Enzyme Immunoassay Kit

Indications for Use: This assay is designed for the in-vitro measurement of specific IgG autoantibodies against tissue transglutaminase (tTG) present in human serum, as an aid in the diagnosis of Coeliac disease.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*Mona Chan*  
Division Sign-Off

Office of In Vitro Diagnostic  
Device Evaluation and Safety

510(k) K040466

Prescription Use   
(Per 21 CFR 801.109)

OR Over-The-Counter Use

(Optional Format 1-2-96)

INDICATIONS FOR USE STATEMENT

Att. 7.2

Device Name: Bindazyme® Human IgA Anti-Tissue Transglutaminase  
Enzyme Immunoassay Kit

Indications for Use: This assay is designed for the in-vitro measurement of specific IgA autoantibodies against tissue transglutaminase (tTG) present in human serum, as an aid in the diagnosis of Coeliac disease.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*Maria Chan*

Division Sign-Off

Office of In Vitro Diagnostic  
Device Evaluation and Safety

510(k) K040466

Over-The-Counter Use     

Prescription Use   
(Per 21 CFR 801.109)

OR

(Optional Format 1-2-96)